Search / 42 results found

from
to
  • Updated

NEW YORK, Sept. 27, 2021 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) will host the 20th Annual NYC Gala on Thursday, October 14 at Cipriani Broadway. In celebration of the MRF's 25th Anniversary, the in-person gala will welcome Emmy award-winning host, producer and New York Times best-selling author Andy Cohen as Gala Emcee. As part of an unforgettable evening to celebrate melanoma patients, survivors and caregivers, Andy will share his personal connection to this community and the life-saving importance of melanoma awareness and early detection.

  • Updated

NEW YORK, Sept. 24, 2021 /PRNewswire-PRWeb/ -- The Beljanski Foundation announces that Nathan Crane has been named to its Board of Directors. An award-winning author, inspirational speaker, plant-based athlete and 20x award-winning documentary filmmaker, Mr. Crane is dedicated to educating and empowering people to live a healthy and fulfilling life.

(The Center Square) – The U.S. Centers for Disease Control and Prevention (CDC) is recommending that medical professionals and clinicians be on alert for infectious diseases among Afghan nationals recently brought into the country, including measles, mumps and rubella, diseases for which Americans have already been vaccinated.

  • Updated

NORTH CHICAGO, Ill., Sept. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® (upadacitinib) in atopic dermatitis and new data on SKYRIZI® (risankizumab) in psoriasis and psoriatic arthritis, at the 30th European Academy of Dermatology and Venereology (EADV) Congress, to be held virtually on September 29-October 2.

  • Updated

PHILADELPHIA, Sept. 23, 2021 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce the US launch of the Zelira Dermatology Business' first product line, RAF FIVE™, through its dermatology subsidiary Ilera Derm LLC ("Zelira Dermatology").

  • Updated

EXTON, Pa., Sept. 23, 2021 /PRNewswire/ -- Just weeks after the FDA approval of Nurtec ODT's label expansion for the preventive treatment of episodic migraine, Eli Lilly announced initiation of a head-to-head Phase IV trial comparing their Emgality to Biohaven's gepant in patients with episodic migraine by the end of this year. With all metrics pointing to extremely strong uptake of Nurtec ODT in the prevention segment, Eli Lilly is looking to proactively defend their brand's opportunity within the market, while also adding to the body of scientific evidence supporting the role of calcitonin gene-related peptide (CGRP) in migraine.

  • Updated

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Sept. 22, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting positive results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ (Nonmelanoma Skin Cancer) at the 2021 TIDES USA event. The hybrid conference is taking place in person at the Boston Convention and Exhibition Center, and digitally on-demand, September 20-30.

  • Updated

SILVER SPRING, Md., Sept. 21, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body). The software, called Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.